Showing results (131-140 of 156) with videos related to
Sort By:
Pageof 16
Japanese Journal of Clinical Oncology|December 9, 2022
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari studyHidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, et al.Breast Cancer (Tokyo, Japan)|June 17, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyToshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, et al.The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.Japanese Journal of Clinical Oncology|November 18, 2022
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trialHiroji Iwata, Rikiya Nakamura, Norikazu Masuda, et al.Cancer Medicine|August 1, 2023
Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06)Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, et al.Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.Therapeutic Advances in Medical Oncology|February 9, 2023
Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancerShani Paluch-Shimon, Patrick Neven, Jens Huober, et al.Cancer Medicine|November 8, 2022
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriersTomoharu Mori, Yusuke Okamoto, Anfeng Mu, et al.Breast Cancer (Tokyo, Japan)|December 8, 2019
Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari studyHidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, et al.Current Medical Research and Opinion|November 3, 2017
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari studyHidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, et al.Pageof 16